BioSpace News Archive

Twist Bioscience Corporation announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences.

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem ® Cell Drug Delivery Technology.

Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, is pleased to provide an update for the Company’s AcuVid™ COVID-19 Rapid Antigen Saliva Test and its U.S. Food and Drug Administration’s Emergency Use Authorization application process.

Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held from 3-7 June.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T.

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced the grant of inducement awards to its newly appointed Senior Vice President, Quality, Mark Tucker, PhD.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO).

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Jefferies Healthcare Conference taking place June 8-10 in New York, New York.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.